Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.

Ailawadhi S, Kelly KR, Vescio RA, Jagannath S, Wolf J, Gharibo M, Sher T, Bojanini L, Kirby M, Chanan-Khan A.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):29-34. doi: 10.1016/j.clml.2018.08.018. Epub 2018 Sep 5.

PMID:
30340993
2.

Development of the Histoculture Drug Response Assay (HDRA).

Hoffman RM, Vescio RA.

Methods Mol Biol. 2018;1760:39-48. doi: 10.1007/978-1-4939-7745-1_5.

PMID:
29572792
3.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM.

Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.

PMID:
26778538
4.

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.

Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL.

Blood. 2014 Oct 16;124(16):2498-506. doi: 10.1182/blood-2014-04-568329. Epub 2014 Sep 8.

5.

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy.

Berenson JR, Hilger JD, Yellin O, Dichmann R, Patel-Donnelly D, Boccia RV, Bessudo A, Stampleman L, Gravenor D, Eshaghian S, Nassir Y, Swift RA, Vescio RA.

Leukemia. 2014 Jul;28(7):1529-36. doi: 10.1038/leu.2014.27. Epub 2014 Jan 16.

PMID:
24429497
6.

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.

Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Waterman GN, Swift RA, Bonavida B, Boccia R, Vescio RA, Crowley J, Chen H, Berenson JR.

Br J Haematol. 2012 Sep;158(6):727-38. doi: 10.1111/j.1365-2141.2012.09241.x. Epub 2012 Jul 18.

PMID:
22804669
7.

Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.

Dubrey SW, Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Bladé J, Heffner LT, Hassoun H, Liu X, Enny C, Ramaswami P, Elsayed Y, Van De Velde H, Mortimer S, Cakana A, Comenzo RL; Velcade Can2007 Study Group.

QJM. 2011 Nov;104(11):957-70. doi: 10.1093/qjmed/hcr105. Epub 2011 Jul 13.

PMID:
21752867
8.

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.

Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL.

Blood. 2011 Jul 28;118(4):865-73. doi: 10.1182/blood-2011-02-334227. Epub 2011 May 11.

9.

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.

Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL; VELCADE CAN2007 Study Group.

Blood. 2009 Aug 20;114(8):1489-97. doi: 10.1182/blood-2009-02-203398. Epub 2009 Jun 4.

10.

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.

Berenson JR, Yang HH, Vescio RA, Nassir Y, Mapes R, Lee SP, Wilson J, Yellin O, Morrison B, Hilger J, Swift R.

Ann Hematol. 2008 Aug;87(8):623-31. doi: 10.1007/s00277-008-0501-0. Epub 2008 May 8.

PMID:
18463870
11.

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, Adams J, Schenkein D, Swift R.

J Clin Oncol. 2006 Feb 20;24(6):937-44. Epub 2006 Jan 17.

PMID:
16418495
12.

Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis.

Yang HH, Ma MH, Vescio RA, Berenson JR.

J Clin Oncol. 2003 Nov 15;21(22):4239-47. Review.

PMID:
14615454
13.

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, Berenson JR.

Clin Cancer Res. 2003 Mar;9(3):1136-44.

14.

Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma.

Parker KM, Ma MH, Manyak S, Altamirano CV, Tang YM, Frantzen M, Mikail A, Roussos E, Sjak-Shie N, Vescio RA, Berenson JR.

Cancer Genet Cytogenet. 2002 Aug;137(1):43-8.

PMID:
12377412
15.

A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.

Berenson JR, Vescio RA, Rosen LS, VonTeichert JM, Woo M, Swift R, Savage A, Givant E, Hupkes M, Harvey H, Lipton A.

Clin Cancer Res. 2001 Mar;7(3):478-85.

16.

Human herpesvirus 8 open reading frame 26 and open reading frame 65 sequences from multiple myeloma patients: a shared pattern not found in Kaposi's sarcoma or primary effusion lymphoma.

Ma HJ, Sjak-Shie NN, Vescio RA, Kaminsky M, Mikail A, Pold M, Parker K, Beksac M, Belson D, Moss TJ, Wu CH, Zhou J, Zhang L, Chen G, Said JW, Berenson JR.

Clin Cancer Res. 2000 Nov;6(11):4226-33.

17.

The role of human and viral cytokines in the pathogenesis of multiple myeloma.

Berenson JR, Sjak-Shie NN, Vescio RA.

Semin Cancer Biol. 2000 Oct;10(5):383-91. Review.

PMID:
11100886
18.

Lack of serologic association of human herpesvirus-8 (KSHV) in patients with monoclonal gammopathy of undetermined significance with and without progression to multiple myeloma.

Ablashi DV, Chatlynne L, Thomas D, Bourboulia D, Rettig MB, Vescio RA, Viza D, Gill P, Kyle RA, Berenson JR, Whitman JE.

Blood. 2000 Sep 15;96(6):2304-6.

19.

Cloning of the first invertebrate MAGE paralogue: an epitope that activates T-cells in humans is highly conserved in evolution.

Põld M, Põld A, Ma HJ, Sjak-Shieb NN, Vescio RA, Berensonb JR.

Dev Comp Immunol. 2000 Dec;24(8):719-31.

PMID:
10906385
20.

Recent advances in multiple myeloma.

Sjak-Shie NN, Vescio RA, Berenson JR.

Curr Opin Hematol. 2000 Jul;7(4):241-6. Review.

PMID:
10882180
21.

Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution.

Douek DC, Vescio RA, Betts MR, Brenchley JM, Hill BJ, Zhang L, Berenson JR, Collins RH, Koup RA.

Lancet. 2000 May 27;355(9218):1875-81.

PMID:
10866444
22.

Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patients.

Vescio RA, Wu CH, Zheng L, Sheen D, Ma H, Liu J, Stewart AK, Ballester O, Noga SJ, Rugo H, Freytes C, Stadtmauer E, Sahebi F, Tarantolo S, Stiff P, Schiller GJ, White M, Jacobs C, DiPersio J, Anderson KC, Berenson JR.

Bone Marrow Transplant. 2000 Jan;25(2):153-60.

23.

The role of human herpesvirus-8 in the pathogenesis of multiple myeloma.

Sjak-Shie NN, Vescio RA, Berenson JR.

Hematol Oncol Clin North Am. 1999 Dec;13(6):1159-67. Review.

PMID:
10626142
24.

HHV-8 infection and multiple myeloma.

Sjak-Shie NN, Vescio RA, Berenson JR.

J Leukoc Biol. 1999 Aug;66(2):357-60.

PMID:
10449181
25.

Identification of a new, unorthodox member of the MAGE gene family.

Põld M, Zhou J, Chen GL, Hall JM, Vescio RA, Berenson JR.

Genomics. 1999 Jul 15;59(2):161-7.

PMID:
10409427
26.

The role of human herpesvirus-8, (HHV-8), in multiple myeloma pathogenesis.

Vescio RA, Berenson JR.

Curr Top Microbiol Immunol. 1999;246:403-8; discussion 409. Review. No abstract available.

PMID:
10396081
27.

HHV-8 is present in multiple myeloma patients.

Berenson JR, Vescio RA.

Blood. 1999 May 15;93(10):3157-9; discussion 3164-6. Review. No abstract available.

28.

HHV-8 and multiple myeloma.

Berenson JR, Vescio RA.

Pathol Biol (Paris). 1999 Feb;47(2):115-8. Review.

PMID:
10192878
29.

Recent advances in the treatment of multiple myeloma.

Henick K, Vescio RA, Berenson JR.

Curr Opin Hematol. 1998 Jul;5(4):254-8. Review.

PMID:
9747631
30.

Methylation of the p16INK4A gene in multiple myeloma.

Tasaka T, Asou H, Munker R, Said JW, Berenson J, Vescio RA, Nagai M, Takahara J, Koeffler HP.

Br J Haematol. 1998 Jun;101(3):558-64.

PMID:
9633902
31.

Multiple myeloma: the cells of origin--a two-way street.

Berenson JR, Vescio RA, Said J.

Leukemia. 1998 Feb;12(2):121-7. Review.

PMID:
9519771
32.

Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma.

Said JW, Rettig MR, Heppner K, Vescio RA, Schiller G, Ma HJ, Belson D, Savage A, Shintaku IP, Koeffler HP, Asou H, Pinkus G, Pinkus J, Schrage M, Green E, Berenson JR.

Blood. 1997 Dec 1;90(11):4278-82.

33.

Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients.

Rettig MB, Ma HJ, Vescio RA, Põld M, Schiller G, Belson D, Savage A, Nishikubo C, Wu C, Fraser J, Said JW, Berenson JR.

Science. 1997 Jun 20;276(5320):1851-4.

34.

Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts.

Vescio RA, Han EJ, Schiller GJ, Lee JC, Wu CH, Cao J, Shin J, Kim A, Lichtenstein AK, Berenson JR.

Bone Marrow Transplant. 1996 Jul;18(1):103-10.

PMID:
8832002
35.

VH gene usage is multiple myeloma: complete absence of the VH4.21 (VH4-34) gene.

Rettig MB, Vescio RA, Cao J, Wu CH, Lee JC, Han E, DerDanielian M, Newman R, Hong C, Lichtenstein AK, Berenson JR.

Blood. 1996 Apr 1;87(7):2846-52.

36.

A CD10-positive subset of malignant cells is identified in multiple myeloma using PCR with patient-specific immunoglobulin gene primers.

Cao J, Vescio RA, Rettig MB, Hong CH, Kim A, Lee JC, Lichtenstein AK, Berenson JR.

Leukemia. 1995 Nov;9(11):1948-53.

PMID:
7475288
37.

Deletion of genetic material from a poly(ADP-ribose) polymerase-like gene on chromosome 13 occurs frequently in patients with monoclonal gammopathies.

Cao J, Hong CH, Rosen L, Vescio RA, Smulson M, Lichtenstein AK, Berenson JR.

Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov;4(7):759-63.

38.

Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity.

Vescio RA, Cao J, Hong CH, Lee JC, Wu CH, Der Danielian M, Wu V, Newman R, Lichtenstein AK, Berenson JR.

J Immunol. 1995 Sep 1;155(5):2487-97.

PMID:
7650379
39.
40.

Multiple myeloma clones are derived from a cell late in B lymphoid development.

Berenson JR, Vescio RA, Hong CH, Cao J, Kim A, Lee CC, Schiller G, Berenson RJ, Lichtenstein AK.

Curr Top Microbiol Immunol. 1995;194:25-33.

PMID:
7534671
41.

The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma.

Vescio RA, Hong CH, Cao J, Kim A, Schiller GJ, Lichtenstein AK, Berenson RJ, Berenson JR.

Blood. 1994 Nov 15;84(10):3283-90.

42.

Correlation of histology and drug response of human tumors grown in native-state three-dimensional histoculture and in nude mice.

Vescio RA, Connors KM, Kubota T, Hoffman RM.

Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5163-6.

43.

The distinction of small cell and non-small cell lung cancer by growth in native-state histoculture.

Vescio RA, Connors KM, Bordin GM, Robb JA, Youngkin T, Umbreit JN, Hoffman RM.

Cancer Res. 1990 Sep 15;50(18):6095-9.

44.

Cancer biology for individualized therapy: correlation of growth fraction index in native-state histoculture with tumor grade and stage.

Vescio RA, Connors KM, Youngkin T, Bordin GM, Robb JA, Umbreit JN, Hoffman RM.

Proc Natl Acad Sci U S A. 1990 Jan;87(2):691-5.

45.

In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture.

Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffman RM.

Proc Natl Acad Sci U S A. 1987 Jul;84(14):5029-33.

Supplemental Content

Loading ...
Support Center